Topic: ulcerative colitis
The trial linked use of the highest dose of the topical TLR9 agonist to a 15% improvement in the clinical remission rate over placebo.
Landos Biopharma picked up $60 million to propel its lead program into phase 2 for ulcerative colitis and Crohn's disease.
The investment extends Abivax’s cash runway out to the middle of 2020, buying the biotech time to find a partner for ABX464.
Celsius’ new deal with Janssen is a win-win—it will feed Celsius' drug discovery and help Janssen work on a treatment for ulcerative colitis.
The Bausch Health subsidiary plans to trial the ex-Biogen S1P receptor functional antagonist in ulcerative colitis.
The trial linked ABX464 to improvements in mucosal healing and performance on a symptom scale, leading Abivax to commit to a phase 2b.
Sublimity Therapeutics hired Jesse Hall as chief medical officer, as it looks to move its lead candidate into a phase 2b ulcerative colitis study.
Kinnon, a former Life Technologies VP, has spent most of the past decade running diagnostic businesses Transgenomic and ZyGEM.
The trial linked the JAK1 inhibitor to significant improvements in symptoms, laying the groundwork for further development in psoriatic arthritis.
Provention Bio has filed to raise up to $50 million in an IPO, which will bankroll several clinical programs.
